Literature DB >> 16110825

Azole and fungicide resistance in clinical and environmental Aspergillus fumigatus isolates.

I Meneau1, D Sanglard.   

Abstract

Aspergillus fumigatus is a human pathogen but it is also a widespread filamentous fungus in the environment. A. fumigatus can therefore be exposed to antifungals used in medical and agricultural environments. Only the class of azoles is used in both of these environments (i.e. voriconazole and itraconazole in medicine; prochloraz, propiconazole or imazalil in agriculture). Exposure to azoles provides the potential for the development of resistance. Several clinical itraconazole-resistant isolates have been reported in A. fumigatus and their resistance mechanisms have been partially resolved. Since limited data exist on the susceptibility of A. fumigatus to both medical and agricultural antifungals, we undertook a drug susceptibility study including clinical (400) and agricultural (150) A. fumigatus isolates (Swiss origin). We tested azoles and also compounds of major antifungal classes used in agriculture (i.e. azoxystrobin, iprodione, benalaxyl or cyprodinil). The results showed that all A. fumigatus isolates were intrinsically resistant to iprodione, benalaxyl or cyprodinil (MIC90 > 32 microg x ml(-1)) and that azoxystrobin minimal inhibitory concentrations (MICs) showed a wide range (0.06 to 32 microg x ml(-1)). MIC ranges of azoles were compound-dependent. MIC90 for voriconazole, itraconazole, imazalil and prochloraz were within a range of 0.13 to 1 microg x ml(-1) and similar between clinical and environmental isolates, whereas propiconazole was the least active compound (MIC90: 4-8 microg x ml(-1)). Ten clinical and 36 environmental isolates with high itraconazole MIC ( > or = 2 microg x ml(-1)) were detected. In clinical isolates, no cross-resistance was observed between itraconazole and all others azoles tested. Several patterns of azole MICs were, however, observed in the environmental isolates. Unexpectedly, a single environmental isolate was voriconazole-resistant (MIC of 16 microg x ml(-1)) but still susceptible to itraconazole (MIC of 2 microg x ml(-1)). Taken together, our results demonstrate the absence of susceptibility of A. fumigatus isolates to non-azole agricultural agents and that there is little impact of azole resistance in both clinical and environmental isolates. When detected, azole resistance was compound-specific.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16110825     DOI: 10.1080/13693780500090826

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  14 in total

Review 1.  Will resistance in fungi emerge on a scale similar to that seen in bacteria?

Authors:  H Hof
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-19       Impact factor: 3.267

2.  Global transcriptome changes underlying colony growth in the opportunistic human pathogen Aspergillus fumigatus.

Authors:  John G Gibbons; Anne Beauvais; Remi Beau; Kriston L McGary; Jean-Paul Latgé; Antonis Rokas
Journal:  Eukaryot Cell       Date:  2011-07-01

3.  Characterization of Aspergillus fumigatus cross-resistance between clinical and DMI azole drugs.

Authors:  Rocio Garcia-Rubio; Irene Gonzalez-Jimenez; Jose Lucio; Emilia Mellado
Journal:  Appl Environ Microbiol       Date:  2020-12-18       Impact factor: 4.792

4.  Azole resistance of Aspergillus fumigatus biofilms is partly associated with efflux pump activity.

Authors:  Ranjith Rajendran; Eilidh Mowat; Elaine McCulloch; David F Lappin; Brian Jones; Sue Lang; Jayesh B Majithiya; Peter Warn; Craig Williams; Gordon Ramage
Journal:  Antimicrob Agents Chemother       Date:  2011-02-14       Impact factor: 5.191

5.  Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain.

Authors:  Klaus Leth Mortensen; Emilia Mellado; Cornelia Lass-Flörl; Juan Luis Rodriguez-Tudela; Helle Krogh Johansen; Maiken Cavling Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2010-08-30       Impact factor: 5.191

6.  Cryptic Aspergillus nidulans antimicrobials.

Authors:  Steve S Giles; Alexandra A Soukup; Carrie Lauer; Mona Shaaban; Alexander Lin; Berl R Oakley; Clay C C Wang; Nancy P Keller
Journal:  Appl Environ Microbiol       Date:  2011-04-08       Impact factor: 4.792

Review 7.  Triazole Resistance in Aspergillus Species: An Emerging Problem.

Authors:  Rocio Garcia-Rubio; Manuel Cuenca-Estrella; Emilia Mellado
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

Review 8.  A Paradigm Shift in the Treatment and Management of Onychomycosis.

Authors:  Aditya K Gupta; Maanasa Venkataraman; Helen J Renaud; Richard Summerbell; Neil H Shear; Vincent Piguet
Journal:  Skin Appendage Disord       Date:  2021-05-11

9.  Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism.

Authors:  Eveline Snelders; Henrich A L van der Lee; Judith Kuijpers; Anthonius J M M Rijs; János Varga; Robert A Samson; Emilia Mellado; A Rogier T Donders; Willem J G Melchers; Paul E Verweij
Journal:  PLoS Med       Date:  2008-11-11       Impact factor: 11.069

10.  Mechanisms and significance of fungicide resistance.

Authors:  Holger B Deising; Sven Reimann; Sérgio F Pascholati
Journal:  Braz J Microbiol       Date:  2008-06-01       Impact factor: 2.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.